{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001027","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.315010+00:00","generated_at":"2026-06-29T18:59:13.141595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing","bullets":["Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.","Cash and marketable securities of $299M as of June 30, 2021, funding pipeline through key milestones.","EDG-5506 Phase 1 MAD study ongoing; topline data from healthy volunteers and Becker patients expected late 2021.","Preclinical EDG-002 cardiac modulator for hypertrophic cardiomyopathy progressing with encouraging data."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001027","json":"https://secwatch.observer/filing/0001157523-21-001027.json","markdown":"https://secwatch.observer/filing/0001157523-21-001027.md","text":"https://secwatch.observer/filing/0001157523-21-001027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/0001157523-21-001027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/a52473423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:59:13.141595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}